LATEST ALERTS
Commercial interest in mushrooms as active ingredients is on the rise – despite legal issues that severely curtail commercial opportunities
Increasing numbers of CBD businesses are marketing products that chime with the wellness trend and now even Playboy is launching a line of CBD products in the US that promise physical and mental benefits
Maria Alejandra Estanga, our market analysts, presented the current status of the topicals market across the most important CBD markets during the Virtual Cannacosmo Health + Beauty Expo on 29st September.
A proposal to be voted on by Brazilian legislators in the coming weeks could legalise the growing of hemp for industrial purposes and cannabis for medical use
The Association for the Cannabinoid Industry (ACI) will move forward with its consortium approach to obtaining toxicology and safety data for CBD with at least 15 companies having signed up and an undisclosed number still in discussion
Studies looking at the potential for CBD to treat or alleviate COVID-19 symptoms continue to progress – with one study hinting at promising results combining CBD with other terpene products
More than a dozen CBD businesses have given their backing to an investigation of the impact of CBD on liver toxicity levels in order to provide regulatory authorities in the US with reliable new data
The pharmaceutical side of the cannabinoid industry continues to grow, with several major announcements expanding treatments and blurring boundaries
CBD-Intel managing director, Tim Phillips, discusses the main facts and issues surrounding CBD and Novel Food status in European markets. He presents the key aspects of the delay, the political issues and the impacts released on the European level and the future challenges for the sector.
The bankruptcy stories continue for cannabinoid firms in the US and Canada as businesses struggle to survive in turbulent times
Expansion plans by two major players suggest confidence in the future of the CBD market in the UK, with one anticipating a continuing rise in sales driven by reactions to the COVID-19 pandemic
A comprehensive list of possible cannabinoid/drug interactions has been published for the first time by researchers at Penn State University in the US
Canopy, the Canadian cannabinoid company, has continued to commit heavily to BioSteel, a sports nutrition company in which Canopy now owns the majority share.
Canadian cannabinoid firm Canopy Growth has signed a multi-year deal with NFL quarterback Patrick Mahomes as part of its advance into the sports nutrition market
Nanotechnology – referring to any kind of technology dealing in very small scales such as atomic, molecular or supramolecular – could improve some of the disadvantages of cannabinoids, such as solubility
Clinical research guidance from the US Food and Drug Administration (FDA) should provide further impetus for cannabis research, which is certain to have an impact on the CBD market
Some recent research has cast doubt on the idea that cannabis compounds may be more effective when taken together
New research into the therapeutic potential of lesser known cannabinoids is progressing with recent discoveries about a host of new compounds
Scientists are increasingly starting to study how differing methods of consumption can affect CBD bioavailability – the ability to enter your bloodstream and induce effects
Registration in the US FDA National Drug Code (NDC) Directory conveys significant benefits even if the FDA does not specifically approve these items as over-the-counter products, according to a CBD company
The FDA’s recent report that fewer than half of the CBD products tested from US store shelves contain the amount of CBD on the label was unwelcome news
A proposed new path forward and extra information presented by Zynerba Pharmaceuticals has thus far not impacted the company’s stock price
The US FDA has criticised CBD products for inaccuracies in labelling the amount of CBD present in products and promised further testing for the sector in the near future
Enforcement activity against food, drink and dietary supplement products placed on the market containing CBD continues despite the inability of companies to proceed with novel food applications due to the EC’s questions over whether CBD constitutes a narcotic under the 1961 UN Single Convention on Narcotics.
Several major developments have all happened at the same time for novel foods. Perhaps most importantly, one of the European Commission’s departments – the Directorate-General for Health and Food Safety – has said it is holding sending any further non-synthetic CBD applications to the European Food Safety Authority for evaluation until it has determined whether CBD technically falls under the definition of a narcotic according to the 1961 UN Single Convention on Narcotic Drugs.
The use of CBD-based products has reduced the consumption of prescription drugs in Italy, according to a discussion paper from an international economics think-tank
An industry association study of the safety and toxicity of cannabinoids is expected to be completed in time to meet submission deadlines to keep CBD-containing food, beverage and supplement products on the UK market
Subscription services are a niche area of the CBD market that could benefit from the ongoing COVID-19 pandemic, providing companies with security and customers with a way to try new products without leaving home
There is some scientific evidence that CBD could encourage smoking cessation and have significant health benefits for those struggling to give up cigarettes
A CBD oil made by Brazilian drugs company Prati-Donaduzzi could become the biggest-selling cannabinoid product on the Brazilian market
Industry leaders say it’s too soon to tell if a newly approved testing method will help address the instability US hemp farmers face due to strict regulations on crops that test above 0.3% THC
A cannabinoid advocacy organisation has called for better rules on the growing of cannabis for research in the US – but declined to say exactly what it would like to see from regulators
Initial reports on the results of the first ever socially distanced 4/20 are a mixed bag
In order to help you keep track of how all this is affecting the CBD industry around the world, all CBD-Intel’s COVID-19-related coverage can now be found in one place here
A new national committee is to be set up in Canada to study all aspects of non-prescription cannabis health products, including CBD products
CBD entrepreneur Christina DiArcangelo tells CBD-Intel that businesses should be using the slowdown to study, reflect, plan – and “get ahead of the ball”
The wider impact of COVID-19 on the CBD sector in the US remains confused in the short term and largely a mystery in the longer term as companies scramble to gather information
Liver toxicity is not really an issue for CBD, but questions remain about its efficacy and how it may affect the efficacy of other drugs. That’s according to leading cannabinoids researcher Kent Vrana
Industry organisations have responded in anger to continued claims being made by some companies about the supposed power of cannabinoids in tackling COVID-19
Also: GW suggests another possible use for Epidyolex; Lawsuit alleges hemp plants were contaminated with pesticide; Elixinol rebrands to move away from medicinal image; Kentucky hemp business goes bust
FDA commissioner Stephen Hahn has told a Congressional subcommittee that more research and data are needed before the FDA is ready to issue a formal policy on CBD products
Bogus claims that products containing CBD may have any beneficial effects in treating or warding off coronavirus risk the wrath of authorities in the US – and could ultimately damage CBD’s reputation
As the COVID-19 pandemic continues to affect people across the world, a swathe of CBD-related events have been called off or postponed. Here is a list of some of the major ones, with dates and details
Unclear testing standards for CBD oil in the UK have led to uncertainty over test results on THC and CBD content for many popular CBD products
Results from a successful phase three clinical trial on the use of Epidiolex to treat drug-resistant Dravet syndrome have been published in the JAMA Neurology journal
A company is looking to use broader evidence permissions to provide the US Food and Drug Administration (FDA) with data on CBD and liver toxicity
Toothpaste giant Colgate is entering the CBD market, researchers have created a laser scanner that can tell the difference between legal hemp and potentially illegal cannabis, and wrestling legend Kevin Nash has become the latest celebrity to endorse CBD, plus more
TobaccoIntelligence, a new service from the team that produces CBD-Intel, is now available, covering the global tobacco and nicotine alternatives sector
Germany’s Federal Institute for Risk Assessment (BfR) recently issued a warning on e-liquids that it believed to be containing synthetic cannabinoids, after at least eight teenagers suffered medical complications from an as yet unconfirmed source
Tom Hanks refutes false claims over endorsement of CBD products, research suggests cannabinoids benefit gene receptor diseases and CBD coffee is set to hit the market, plus more
Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.
"*" indicates required fields
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
